Wednesday, March 28, 2012

Proteome Sciences Up Big On Alzheimer's Test


Proteome Sciences (LON:PRM) is up big today on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer’s disease.

The Company announced that in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, the completion of the large, 1,000 sample Alzheimer’s Disease (AD) biomarker validation study. Preliminary results indicate that these biomarkers have significant potential diagnostic and prognostic utility that could form the basis of a series of simple blood tests for the diagnosis and management of this debilitating disease.

All American Investor


Subscribe to All American Investor
Enter Your Email Address

It is currently estimated that 60% of people with AD have not been properly diagnosed and therefore are not being given vital drugs and care. The capability to distinguish between the levels and progression of the disease will enable drug developers to substantially improve patient care and people with mild cognitive impairment are likely to benefit the most from such disease-modifying drugs.

Read more details here -- Completion of Alzheimer’s Plasma Biomarker Study, Data Demonstrates Significant Diagnostic and Prognostic Utilities

Learn more about Alzheimer's and dementia, follow the latest developments in medical science at the Alzheimer's Reading Room.

More details on Proteome



Original content Bob DeMarco, All American Investor